Biogen to discontinue development of older Alzheimer’s drug Aduhelm
(Reuters) – Biogen Inc said on Wednesday it would terminate
Biogen,
ISS backs election of Langer to replace former Biogen director Denner
By Svea Herbst-Bayliss NEW YORK (Reuters) – Proxy advisory firm
Factbox-Who can get the newly approved Eisai and Biogen Alzheimer’s drug?
(Reuters) – The U.S. Food and Drug Administration on Friday
Eisai, Biogen Alzheimer’s drug could be available to some next year
By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) –
Former J&J executive emerges as front-runner for Biogen top job – STAT News
(Reuters) – Mathai Mammen, a former executive at drugmaker Johnson
Biogen Inc. Agrees to Pay $900 Million to Settle False Claims Act Allegations Related to Improper Physician Payments
BOSTON – Pharmaceutical company Biogen Inc. (Biogen), based in Cambridge,
Biogen CEO to leave as Alzheimer’s drug struggles
(Reuters) – Biogen said on Tuesday its Chief Executive Michel
Alzheimer’s patient groups pressure U.S. to pay for Biogen drug
By Deena Beasley – Patient groups are mounting a public
REPORT: Biogen, Eisai Began Application For Alzheimer’s Drug
Biogen, and its Japanese partner Eisai, announced Monday that it